Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell DiseaseGlobeNewsWire • 07/27/22
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate UpdatesGlobeNewsWire • 07/26/22
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This WeekThe Motley Fool • 07/08/22
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of CancerGlobeNewsWire • 06/07/22
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/22
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/18/22
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta ThalassemiaZacks Investment Research • 05/13/22
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaGlobeNewsWire • 05/12/22